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Summary.-Tumours were induced s.c. in C3H/uip, SJL/uip, DBA/2 uip, C57BL/6 uip
and BDF1 mice by different doses of methylcholanthrene (MCA) diluted in oil: 1 mg,
0.1 mg and 0.01 mg. In each mouse strain, tumour frequency showed a different
decreasing pattern in relation to the decreasing dose of MCA. Tumour latent period
(LP) increased between the lmg and 0-1mg doses of MCA, but the 0-01mg dose
induced tumours with a similar or shorter LP than those tumours induced by 1 mg.
Half of the tumours were treated with two injections of intratumoral (IT) BCG. The
strains of mice differed in their sensitivity to this treatment, but only tumours
induced by 0-01 mg MCA were sensitive to IT BCG. The induction of tumours by
MCA pellets gave similar results. After transplantation of the untreated tumours,
very few were cured by BCG treatment. Analysis of the role of tumour LP, growth
rate and immunogenicity favours a slow growth rate as the most important charac-
teristic for BCG sensitivity of the primary tumour. The tumours induced by 0-01 mg
MCA were less immunogenic than those induced by 1 mg MCA, but the difference
was not significant. This finding permits us to exclude an important role for tumour
immunogenicity in the sensitivity of the primary tumour to BCG.
As RECENTLY CLAIMED by Baldwin
(1976), Bartlett et al. (1976) and Martin
et al. (1977) the results oftumour immuno-
therapy assays with transplanted tumours
induced by large doses of carcinogen are
not easily applied to human tumours.
"Spontaneous" tumours are not fre-
quent enough in animals to allow the study
of a particular treatment in many animals
over a short time. A few animal strains
have a high frequency of "spontaneous"
tumours, but they have been selected for
this character and do not represent a
natural situation.
We attempted to avoid some of these
problems by testing a tumour-immuno-
therapy system on primary tumours in-
duced by various doses of carcinogen in
different strains of mice. The immuno-
therapy used, injection of BCG into the
tumours, was first described for the treat-
ment of human melanoma (Morton et al.,
1970) transplanted guinea-pig tumour
(Zbar & Tanaka, 1971) and transplanted
rat tumours (Baldwin & Pimm, 1971;
Chassoux & Salomon, 1975). Indeed this
mode of treatment contains two of the
important conditions forsuccessful tumour
immunotherapy compiled by Bast et al.
(1976): a small tumour burden and direct
contract between BCG and tumour cells.
The BCG strain from the Pasteur Institute
has been shown to be one of the
most effective for tumour immunotherapy
(Lagrange, 1978).
Some tumour characteristics have been
studied to define more precisely the con-
ditions of successful immunotherapy.
Baldwin & Pimm (1973a, b) studied the
role of tumour immunogenicity in the
success of BCG treatment. Their work
shows that the growth of several non-
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immunogenic transplanted tumours is not
suppressed by BCG (Baldwin & Pimm,
1973a) but that i.v. injection of BCG may
inhibit the growth of pulmonary meta-
stases of a weakly immunogenic tumour
(Baldwin & Pimm, 1973b).
As far as we know, no systematic
studies have been done on other tumour
characteristics. Tokunoga et al. (1974)
have shown that sensitivity to intra-
tumoral (IT) BCG (regression plus re-
currence of delay in growth) of primary
tumours induced by 0 5 mg MCA was
positively related to a short latent
period (LP). Bartlett (1972) has also
demonstrated an inverse correlation be-
tween the LP of the primary tumour and
its growth rate. In the present study, the
LP, growth rate and immunogenicity of
primary tumours were examined in rela-
tion to the success or failure of therapy
by IT BCG.
MATERIALS AND METHODS
Animals. Male and female C3H/uip, SJL/
uip, DBA/2 uip, C57BL/6 uip and BDFI
mice, 2 months old, were obtained from the
breeding facilities of our Institute. The pan-
geneic mice, 2 months old, were obtained
from a random cross of mice of different
strains; they were used at the 5th generation
ofrandom breeding.
Tumours.-Fibrosarcomas were induced
by s.c. injection of041 ml of olive oil contain-
ing 1 mg, 0-1 mg or 0-01 mg ofMCA (Eastman
Kodak). In a second experiment, this mode of
induction was compared with the s.c. im-
plantation of an MCA pellet (Prehn, 1975)
containing °/ (0.2 mg), 0.50o (0-02 mg) or
0-050o (0-002 mg) MCA.
Latent period (LP). Animals were ex-
amined for tumour appearance during one
year. LP was recorded when the tumour
diameter was 4 mm.
Treatment of tumours.-On Day 0 (day ot
MCA injection) mice were randomly desig-
nated to be treated or not treated by BCG
when a tumour appeared.
When a primary tumour diameter reached
4-9 mm, the animal was given 2 IT injections
of 1 mg BCG each (fresh BCG or immuno
BCG ofthe Pasteur Institute) one week apart.
The same treatment was applied to trans-
planted tumours (Chassoux & Salomon,
1975).
For the C. parvumn treatment of tumours,
the same schedule as for BCG was used. The
only change was the dose used for each ofthe
2 injections: 109 (0 07 mg) of heat-inacti-
vated C. parvum (No. 4182 strain of the
Pasteur Institute, provided by R. Ducluzeau,
CRNS, Jouy-en-Josas, France).
The mice were considered as cured when no
tumour wvas present at least one year after
the injection of MCA, after a tumour had
appeared at that site. When a node was still
detected at the old tumour site, a histological
study was done to exclude the possibility of
an active tumour centre.
Transplantation.-Untreated tumours were
excised when their diameters were 10-12 mm.
At this size, the tumour mass was free of
necrosis. Fragments of the tumour uwere
frozen at -80°C in Hanks' medium contain-
ing 10° glycerol. These fragments w"ere
rapidly thawed and transplanted to animals
that had been wirhole-body irradiated with
400 rad X-rays 24 h previously. Tumours that
developed were then transplanted to different,
untreated animals for the study of BCG
immunotherapy oroftumourimmunogenicity.
Measurement of growth rate. For both
primary and transplanted tumours, the
growth rate was defined as the number of
days necessary for the tumour to treble its
diameter (4 to 12 mm). During this period the
tumour growth is generally linear.
Measurement of immunogenicity. - The
immunogenicity ofthe tumour was examined
for untreated tumours induced by 1 mg or
0-01 mg MCA. Each tumour was transplanted
s.c. on the abdomens (SCV) of 6-8 mice as a
fragment of about 1 mm3. When the tumour
diameter reached 10-12 mm, the tumour was
excised. Two weeks after the excision, a frag-
ment of the same tumour was transplanted
s.c. on to the backs (SCD) of these mice.
A recurrence at the first implantation site
excluded the animal from the record oftakes.
The take and growth rates of the second
tumour grafts indicate, when compared with
those of the first tumour grafts, the degree of
immunization of the animals. Each tumour
was classified for immunogenicity (4 to 0)
from the plotted results so that the different
groups could be compared.
Immune response to sheep red blood cells.-
At Day 0, 2 x 108 SRBC (Pasteur Institute)
in 0-2 ml of phosphate-buffered saline were
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injected i.p. into each pangeneic mouse. At
Day 5, the number of direct plaque-forming
cells was determined for the spleen of each
animal by Jerne's method.
RESULTS
Tumourfrequency
Table I shows the various sensitivities of
the different strains of mice to the induc-
tion of tumours by MCA. The lmg dose
gave the most tumours in all mouse
strains. We can distinguish the strains by
the different patterns of decrease in
tumour frequency as a function of de-
crease in MCA dose. For instance, the
SJL strain still had a hiigh frequency of
tumours at 0-01 mg MCA (13/19) and the
C57BL/6 already had a low tumour
frequency at the O-mg dose (2/15).
The strains in increasing order of sensi-
tivity to MCA induction were: C57BL/6,
C3H, DBA/2 and SJL. The pattern of
decreasing tumour frequency among the
Fl hybrids (C57BL/6 x DBA/2) was simi-
lar to that ofthe C57BL/6 strain, but with
a higher frequency for the 2 lower doses
ofMCA.
Latentperiod (LP)
Tumour appearance was recorded
separately for male or female mice be-
cause of significant sex differences in the
LP of tumours induced by 1 mg MCA
(C3H and SJL).
Tables II and III show that, in general,
the LP of the tumour increased between
the 1mg and 01mg doses (SJL Y,
P < 0 05; C3H S, P < 0.01). The tumours
induced with 0 01 mg MCA had an LP
similar to or shorter than (C3H Y,
P < 0-05; BDFI 1, P < 0-01) those induced
by 1 mg. P values were determined by the
Mann-Whitney U test.
BCG treatment of the primary tumours
No cure was seen for the lmg MCA-
induced tumours, and only one cure for
those induced by 01 mg (Table IV).
TABLE I.-Tumour frequency after injection of 1, 01 or 0-01 mg of MCA. P based on
x2 test after Yates' correctionfor small samples
Strain
MCA , --
(mg) C3H SJL D)BA/2 C57BL/6 BDFI Comparison P*
I 29/30x0 13/14 5/8 28/30X0 11/14x0 DBA/2-C3H <0(05
0.1 9/14X 12/13 11/15X 2/15x 11/29x C57BL/6-C3H, SJL, DBA/2 } <001
BDFI-SJL, DBA/S f
0-01 12/290 13/19 1 1/26x 3/300 6/150 C57BL/6-C3H, SJL, DBA/2 < 0-01
C57BL/6-BDF1, C3H-SJL < 0 05
Com- x-x and
parison 0-0
P <0-01
- x-x x-x and x-x 0-0
0-0
<005 <001 <0*01 <005
TABLE II.-Tumour latent period (in days) measured to when the tumour is about 4 mm
in diamieter. LPs of tumours that regressed spontaneously are excluded
MICA
(mg)
1 Alean
Range
01 Mean
Range
(-
(79-
0-01 AMeain 9
Range (56-
V
Strain
- A-
C3H SJL
4-A
37 58-3 634 745
-271) (53-66) (43-140) (67-77)
L5 14 5 8
- 9852 907 7
(69-102) (63-145)
9 12
39 7 81 83-4
-265) (52-139) (70-98)
L;2 5 8
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TABLE III.-Tumour latent period (in days) measured to when the tumour is about 4 mm
in diameter. LPs of tumours that regressed spontaneously are excluded
Strain
C57BL/6
102-4 106-5
3-225) (70-295)
5 28
0.1 Mean 139-9
Range (70-271)
n 11
001 Mean 991
Range (48-161)
n 11
198-5
(141-256)
2
63
1
89-1
(49-138)
11
109 64-2
(78-141) (61-72)
2 6
TABLE IV.-Cure after BCG treatment of primary tumours. The primary tumours were
treated when their diameter was 4-9 mm by 2 injections of 1 mg ofBCG one week apart
Strain
C3H
BCG 0/11
Control 0/29
SJL DBA/2 C57BL/6 BDF1
0/6 0/1 0/10
0/7 0/4 0/15
0.1 BCG 0/5 0/6 0/5t
Control 0/15 0/7 0/4
0.01 BCG 2/5 0/6 7/8t
Control 0/6 0/5 5/8
0/2
0/3
Comparison
p
t t
0009
There were many cures for the 0T01 mg
MCA-induced tumours, but the sensitivity
of the tumour to IT BCG varied between
the strains of mice. The SJL strain was
the most resistant and the DBA/2 strain
the most sensitive of those studied. In the
group of 0.01 mg MCA-induced tumours
we also observed spontaneous regressions:
6/23 tumours regressed spontaneously
compared with 12/22 tumours that re-
after IT BCG (X2=3.79,
A comparison ofsurvival among treated
and untreated mice was not made, be-
cause the untreated tumours were excised
and frozen for the later study of BCG
immunotherapy on transplanted tumours.
BCG treatment of the transplanted tumours
BCG cured very few transplanted
tumours (Table V): 2/6 SJL tumours
t-t
0-056
transplanted from a lmg-induced tumour
(1/5 spontaneous regression was recorded
in the controls) and 1/5 C57BL/6 tumours
transplanted from a 0 01mg-induced
tumour.
In progressors, the survival time after
treatment with IT BCG was compared by
Student's t test with survival time of
untreated animals, and was similar in the
2 groups. BCG treatment did not affect
the tumour growth rate either way.
Comparison of the modes of tumour induc-
tion: oil and pellet
Only the C3H strain of mice was used
in this experiment.
As shown in Table VI, the 2 modes of
induction did not differ in the frequency
of tumours produced, or in the sensitivity
of such tumours to BCG or C. parvum
MCA
(mg)
1
DBA/2
A
Mean
Range
n
(6
BDF1
77-7
(65-108)
11
MCA
(mg)
1 0/4t
0/7
1/7
0/3
3/3t
1/4
Total
0/32
0/62
1/23
0/31
12/22
6/23
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TABLE V.-Survival time (days+s.d.) and number of cured animals after BCG treatment
of the tumours at the second transplantation. The tumours were treated whenthey were
4 mm in diameter by 2 injections of 1 mg BCO one week apart. LP refers to the
primary tumrour. Figuresfor control animals are not given
MCA (mg)
- - --
Strain
C3H LP (days)
control (days)
BCG (days)
cure/treat.
S.JL LP
control
BCG
cure/treat.
LP
control
BCG
cure/treat.
LP
control
BCG
cure/treat.
LP
control
BCG
cure/treat.
DBA/2 LP
control
BCG
cure/treat.
LP
control
BCG
cure/treat.
LP
control
BCG
cure/treat.
C57BL/6 LP
control
BCG
cure/treat.
LP
control
BCG
cure/treat.
1
60
59.5 (5)
67-4 (3)
0/6
140
43-8 (7.2)
53.5 (4)
2/6
63
31-3 (1-7)
30-9 (1-7)
0/8
100
40-5 (4 2)
40-3 (1.9)
0/6
61
29-2 (1-2)
30 3 (1-5)
0/6
82
42-6 (4*8)
36 (3)
0/5
treatment. The effect of the treatment
was similar to that seen in the first experi-
ment: cures were obtained only for
tumours induced by the lower doses or the
lower concentrations of MCA.
The two modes differed in the LP ofthe
tumours that developed: there was an
increase in LP parallel to the decrease in
concentration of MCA in pellet-induced
tumours. However, the differences were
not significant.
69
39.
39
0/l
70
34-.
30 X
0/,
151
46
52-
0/1
0-1 0.01
56
8 (2.4) 62-7 (5)
(2.3) 59 (2)
'6 0/6
76
2 (4.4) 49-6 (3-5)
4 (4X1) 38-5 (6.7)
'5 0/6
52
43-8 (3 6)
46-2 (2.3)
0/6
139
36 (2.3)
32-2 (5.4)
0/6
71
72 (8-9)
64 (9 4)
0/5
48
(0) 27 (1-3)
4 (3 3) 28-7 (1)
8 0/6
161
41-1 (1X7)
42 (1.1)
0/8
141
46-3 (3 8)
41 (2 5)
0/6
256
40 (4)
40 (2-1)
0/6
141
58-3 (3.9)
53-3 (2.7)
0/3
77
64-2 (6*7)
49-3 (2.3)
1/5
Sensitivity to BCO treatment ofthe primary
tumours in relation to latent period
Table VII shows the results obtained
after the classification of tumours (in-
dependently of the dose of MCA used for
their induction) for their sensitivity to
BCG treatment: (-) resistance, (±) re-
gression and recurrence, (+) cure. In
DBA/2 and BDF1 mice, the early tumours
were more sensitive to BCG treatment
than the late tumours. The significance of
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TABLE VI.-Comparison of the induction of tumours by MCA in oil or in Millipore
paraffin pellets, in the C3H strain, on the basis offrequency, mean latent period and
sensitivity to BCG or C. parvum treatment of tumours induced by the 2 modes of induc-
tion. No significant differences in cure rates (X2 test). The only significant difference
in LP (Mann-Whitney U test) is between 1 and 0.1 my MCA (P < 0 01)
Tumour
MCA frequency
1 mg 10/10
01 mg 15/15
0 01 mg 11/20
5% 10/10
0.5% 14/15
0.05% 12/20
0% 0/10
LP in days
(s.d.)
70 9
(6.1)
88-8
(7.1)
68-1
(3 6)
90-8
(7 0)
107-1
(10.2)
102
(9-1)
Cure rate
BCG C. parvum
0/5 0/5
0/8 1/7
1/6 2/5
0/5 0/5
0/5 0/5
1/5 2/6
TABLE VII.-Comparison between latent period and sensitivity to BCG
primary tumours
Strain
Sensitivity
to BCG
treatment*
+ Mean LP
s.d.
n
+ Mean LP
s.d.
n
- Mean LP
s.d.
n
Comparison
Pt
C3H SJL DBA/2
(1+0-1+0-01)t (1+0-1+0-01) (1+0-1+0-01)
74-5 - 92x
(2.5) (8 2)
2 7
72
(11.6)
3
77-4
(3 8)
16
79-8
(6.9)
5
76-8
(7 6)
12
132
(48)
2
139-6X
(23)
5
x-x
0 053
C57BL/6
(1)
102-1
(8 5)
9
treatment of
BDF1
(1+0-1+0-01)
61.8x
(1.7)
4
72
1
97-5x
(10-1)
10
x-x
<0*05
* +, cure; ±, regression and recurrence; -, resistance.
t mg doses of MCA used to induce the primary tumours.
$ P based on the Mann-Whitney U test.
LP values for tumours which regressed spontaneously are: 91-2 (8 7)
the only BDF1 tumour.
this difference is due mostly to the
earliness of the tumours induced by 0.01
mg MCA in oil.
Tumour growth rates
Primary tumours (Table VIII).-We cal-
culated the growth rates for untreated
(control) and treated (BCG) tumours of
each group. Some tumours could not be
for 5 DBA/2 tumours and 83 for
recorded in this table because ofthe limits
chosen.
For the C3H strain, the tumour growth
rate was similar for treated and untreated
tumours. All tumours induced by the
lowest dose of MCA had a slow growth
rate.
For the SJL strain, the tumour growth
rate was nearly the same for every MCA
Oil
Pellet
-~~~~~~~~~ \~~~~~~
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TABLE VIII.-Effect ofBCG treatment on growth rate* ofprimary tumours
Strain
, L \~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MCA (mg)
1 Days
s.d.
n
0.1 Days
s.d.
n
C3H
Control BCG
22-4 27-3+
(4.4) (6.5)
14 14
28-7 29-4
(3.2) (6-0)
3 5
SJL DBA/2
Control BCG Control BCG
27 36 30 64
(665) (9.9)
5 5 1 1
33-5 79-6 125-5 152
(2.8) (37) (84-8) (58-6)
4 5 2 5
0 01 Days 79 82-4+ 30 61
s.d. (35-2) (36-4) (13-6) (15)
n 5 5 3 4
C57BL/
Control
35-5 c
(9.4) (2
4 1
17-5
(1.8)
2
142 195
1 1
/6 BDF1
BCG Control BCG
32 52-7 97-8
21-7) (15-7) (49.4)
t0 3 4
62-8
(16.3)
4
44
<0-05
* Expressed as days required for trebling of tumour diameter (from 4 to 12 mm).
TABLE IX.-Comparison ofgrowth rate* ofprimary and twice-transplanted tumours
Strain
C3H
Prim. Transpl.
66 t 31-3
0 1 29 t 10-8
0-01 208 t 30-3
SJL
A
Prim. Transpl.
20 22-7
39 t 18-8
24
38
33
14
t 19-5
t 18-5
DBA/2
Prim. Transpl.
30 t 15
21 20-7
87 t 16-5
31 25-5
142 t 9-3
105 t 16
C57BL/6
Prim. Transpl.
13 13-2
15
20
25
25
18-2
12-3
21-5
23
* Days required for trebling tumour diameter (from 4 to 12 mm).
t =Significant difference between the tumour growth rates.
dose used. The BCG seemed to delay the
growth of the tumours in each group, but
no difference was significant.
We have little data for the DBA/2
strain because some tumours never
reached 12 mm in diameter. The data
shown in Table VII indicate a decrease in
growth for the tumours induced by 0-1 mg
and 0-01 mg MCA as compared to 1 mg,
and a slight decrease in growth rate after
BCG treatment.
For the C57BL/6 strain and the BDF1
mice, we have too few isolated cases for
valuable comment. In general, the tumour
growth rate decreased (i.e. trebling time
increased) in parallel with the MCA dose
used for the induction of the tumour:
(1 mg) 24-6 days+ 3-2 (27); (0-1 mg) 46-3
38
days + 16-6 (11); (0-01 mg) 69-7 days + 22-5
(10). P values from the Mann-Whitney U
test are 0-052 for 1 mg vs 0-1 mg and 0-062
for 1 mg vs 0-01 mg.
A comparison of all tumours shows no
difference of growth rate between early
and late tumours: LP <110 days:38.1 +
6-4 (37); LP >110 days:46-1+27-3 (7);
P = 0-42 (Mann-Whitney U test). The 110-
day cut-off for the latent period was
chosen because beyond this limit 3 strains
and the BDF1 mice showed a lack of
tumour appearance for various periods of
time.
Transplanted tumours.-The growth rate
of the primary tumour was compared to
the same tumour after transplantation
(mean growth rate of 4-7 tumours). When
Comparison
p
MCA
(mg)
1
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TABLE X.-Tumour immunogenicity
Strain
MCA ,-
(mg) C3H SJL DBA/2 C57BL/6
1 0, 1, 1 05, 1, 1, 0-5, 05, 05 0, 05, 1, 2,
2-5 35, 35, 3-5
0-01 0, 05, 0.5,
05, 2-5
0, 0 5, 1, 1 0, 0-5 0*5, 1
Mean
range
n
Mean
range
n
Total
1-32
(0-35)
17
0-65
(0-25)
13
The immunogenicity value is calculated for each tumour after transplantation SCV to 6-8 mice, tumour
excision, and retransplantation of the same tumour SCD. The comparison of takes of the first tumour graft
(0-25 or 26-75 or 76-100%) with the takes of the second graft, plus the delay in the growth of this second
graft (+ or -) give to each tumour a value in the classification representing the degree of immunogenicity:
from 4 (high immunogenicity), down to 0 (no immunogenicity).
at least one of these 4-7 tumours had a
growth rate similar to that of the primary
tumour, we discount the difference.
The results are shown in Table IX. No
tumour had a slower growth after trans-
plantation, and 10/19 tumours had a
faster growth.
Immunogenicity
The legend of Table X indicates the
method ofcalculating the immunogenicity
of each tumour from 4 (high immuno-
genicity) to 0 (no immunogenicity).
The mean immunogenicity of the lmg
group was higher than that of the OOlmg
group, but the difference was not signifi-
cant (P = 0.088). It is noteworthy that, in
the group of tumours induced with the
highest dose of MCA, 7/17 had no or little
immunogenicity (0-0.5). If we separately
consider the tumours induced in females,
we obtain: 1-7 (0-3.5) as mean immuno-
genicity for 10 tumours induced by 1 mg
MCA and 0-61 (0-2 5) as mean immuno-
genicity for 9 tumours induced by 0-01 mg
MCA. The difference is significant by the
Mann-Whitney U test: P < 0 05.
Immune response to SRBC after injection
ofMCA
The Figure shows the measurement of
systemic anti-SRBC responses (as per-
centages of the control) 7, 14 and 79 days
after the injection of 1, 01 or 0*01 mg
MCA.
The animals injected with 1 mg had a
100.
50
10.
days
FIG.-The anti-SRBC responses after one
injection of MCA are plotted as the
percentage ofthe control response with time
between the injection of MCA and the
injection of SRBC: +-+ 1 mg MCA;
0- 001 mg MCA; A-A 001 mg MCA.
marked depression in the anti-SRBC
response 7 days (P<0-01) and 14 days
(P < 0 01) after the injection of MCA. By
Day 79, the animals had begun to recover
part oftheir response.
After the injection of 04 mg, the
response was also rapidly depressed, but
this depression was less and shorter-lived
(Day 7: P < 0-01, Day 14: non-significant)
than with the 1 mg dose.
After the injection of 0 01 mg, we noted
a depression in the anti-SRBC response
that was stronger than that after the
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0.1mg dose; this depression was still
present at Day 79 (P < 0-01).
1)ISCUSSION
The various sensitivities of different
mouse strains to tumour induction by
MCA were described a considerable time
ago (Chouroulinkov et al., 1961).
The latent period (LP) of tumours in-
duced by low doses or concentrations of
carcinogen has been shown to be longer
than that of tumours induced by high
doses or concentrations (Slaga et al., 1974;
Prehn, 1975). This may be linked with the
immunodepressive potency of the carcino-
gen dose (Stutman, 1975). Indeed, after
induction of tumours by a low concentra-
tion ofMCA in pellet, we obtained a slight
increase in the tumour LP. On the con-
trary, results from the use of a very low
dose of MCA in oil (0-01 mg) seem to be
inconsistent with this supposition, be-
cause the tumours induced with 0-01 mg
MCA in oil had similar or shorter latent
periods than the lmg-induced tumours.
Our study on the immunodepressive
potency of the 3 doses in pangeneic mice
shows a second discrepancy. The lmg
dose induces a strong depression which is
probably due to its toxicity towards all
lymphocytes. With the 01mg dose, we see
a slighter depression, with an earlier re-
covery of the immune response. But with
the O0Olmg dose, the depression is at
about the same level as with the 1mg
dose, and continues to Day 79. There is no
continuous proportionality between the
dose ofMCA and the level and duration of
the induced immune depression. These
results could partly explain the appear-
ance ofearly tumours after the lower dose.
A more extensive study is needed to con-
firm this point.
Primary tumours induced by 0-5 mg of
MCA were treated with IT BCG by
Tanaka (1974) and Tokunoga et al. (1974).
In Tanaka's work, 1/7 tumours grew more
slowly after one injection of 2 x 107 BCG
organisms. In Tokunoga's work, after one
injection of 1 x 108 BCG organisms: 8/30
tumours grew more slowly, 5/30 regressed
and then recurred. In these two experi-
ments, there was no cure of tumours. No
spontaneous regressions were recorded and
in Tokunoga's work, only 1/19 tumours
grew more slowly in the control group.
This absence of cure is consistent with our
results, because we obtained cures of
tumours only when they were induced by
0-01 mg MCA; the tumours induced by
higher doses were resistant to BCG. We
have previously observed (Chassoux &
Salomon, 1975; Salomon & Lynch, 1976)
that transplanted mouse tumours induced
by large doses of carcinogen were rarely
cured by IT BCG. This was confirmed in
the present experiment with transplanted
tumours.
These results lead us to distinguish
between the tumour growths in the
primary host and in the transplanted
host. In tumour groups where we observe
spontaneous regressions, the primary
tumour grows at the same time as spon-
taneous rejection mechanisms develop. It
is only later that one ofthese antagonistic
phenomena wins over the other. At this
time, the BCG injected IT has its greatest
effect, creating a larger number of re-
gressions than the spontaneous rejection
mechanisms alone. It is likely that spon-
taneous rejection mechanisms and BCG-
stimulated mechanisms partly overlap;
macrophages and NK cells are probably
more involved in the response to these
weakly immunogenic tumours than are T
cytotoxic lymphocytes. These cell popu-
lations are usually implicated in the
thymus-independent immune surveillance
(Meltzer, 1976; Wolfe et al., 1977). After
trocar transplantation, the period be-
tween the implantation of tumour cells
and the palpable tumour appearance is too
short to allow the same mechanisms to
develop. A similar phenomenon to that
observed with primary tumours would
perhaps be seen if fewer cells were trans-
planted. However, we cannot be sure that
the transplanted tumour that arises does
not result from selection of the most
aggressive cell or cells.
We have attempted to correlate tumour
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sensitivity to IT BCG with some charac-
teristics of the tumour: delay of appear-
ance, growth rate and immunogenicity.
Tables II, III and VI show that the
tumours induced by 0-01 mg of MCA in
oil are early, and the tumours induced by
0 05%0 MCA in pellet are late. These two
groups of tumours are both induced by a
low dose of MCA and occur at a low
frequency. The finding that they are both
sensitive to IT BCG suggests that the
latent period is not an important factor in
tumour sensitivity.
The tumour growth rate is the result of
many phenomena, among which some are
intrinsic characteristics of the tumour-cell
population (generation time, proportion
of cells in Go, proportion of cells loss, etc.)
and those which are dependent on host-
tumour relationships, including anti-
tumour immune reaction, with its rejec-
tion and enhancement components. The
studies of tumour growth rates and induc-
tion doses show that the two parameters
are not independent: the higher the dose
of MCA, the faster the growth rate of the
tumour.
The slower growth rate of the tumours
induced by 0-01 mg MCA in oil does not
seem to be linked to a long LP, as sug-
gested by Bartlett (1972). The mechanism
of MCA action on cell transplantation by
mutation leads us to suggest a propor-
tional relationship between the number of
genes affected and the dose of MCA. We
assume that, among survivor cells, the
largest doses of MCA induce more muta-
tions and give a more heterogeneous popu-
lation of transformed cells; the clones
which are best equipped for growth rate,
invasiveness and immune depression of
the host are more likely at the origin of
the resultant tumours. By contrast, the
tumours induced by low doses may be
more homogeneous and oflow malignancy,
characteristics that would be involved in
the spontaneous regressions.
For 9/19 tumours, growth rate was un-
changed after transplantation, whereas
the other 10/19 tumours showed an
accelerated rate (although we partly
avoided immune selection by whole-body
irradiation of the animals before the
tumour graft). An increase in growth rate
after transplantation of primary tumours
has already been observed by Foley (1953).
The fact that BCG acts particularly on
primary tumours which have a low
growth rate could explain the frequent
failure of BCG therapy on transplanted
tumours with an accelerated growth rate.
Tumour immunogenicity was considered
by Baldwin & Pimm (1973a) to be in-
volved in the success of BCG therapy.
Two of their experimental conditions
differ from ours: 1, they used trans-
planted tumours instead of primary
tumours, and 2, they made suppression
whereas we made regression experiments.
It is very likely that host-tumour rela-
tionships are not the same in a system
where the tumours start from transformed
cells and develop through a selection pro-
cedure in the organism and in systems
where a large number of relatively
homogeneous tumour cells from a stabil-
ized transplanted tumour are injected in
one shot into a healthy animal.
In our preliminary results, although we
obtain a lower mean immunogenicity for
tumours induced by 0-01 mg MCA in oil
than for the tumours induced by 1 mg
MCA in oil, the difference is not statistic-
ally significant. This lack of significance is
probably due to thedispersionofthevalues
brought about by the presence of non-
immunogenic tumours among those in-
duced by 1 mg MCA. The appearance of a
large number of non-immunogenic
tumours has been observed by Bartlett
(1972). In a comparison of early tumours
induced by 3 different concentrations of
MCA, Prehn (1975) also obtained a mar-
ginal difference between the immuno-
genicity of groups induced by a high con-
centration and those induced by a low
concentration of MCA. This tendency
towards a reduction of immunogenicity
with decreasing dose of MCA leads us to
exclude an important role for a high
immunogenicity in the mechanisms of
BCG action on primary tumours.
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The mechanism of BCG action in this
system is not known, but nonspecific
reactions must be involved. Lynch &
Salomon (1977) have shown that the in-
jection of BCG into the tumour provokes
the penetration of blood components,
humoral and cellular, into the tumour
circulation, where they did not have
access before. At the time ofthis reaction,
4 types of cells can be involved in the
cellular anti-tumour reaction of the host:
T cells and cells acting in antibody-
dependent cellular cytotoxicity which
involve specific anti-tumour immunity,
cytotoxic macrophages, and NK cells
which involve nonspecific immune rejec-
tion. We do not know which cell type or
antibody plays a role in the observed
tumour regression, as BCG can stimulate
all these potential effectors. In the case of
transplanted tumours, we have shown
(Salomon & Lynch, 1976) that, depending
on the tumour, cure after IT BCG some-
times produces specific anti-tumour im-
munity. In the present experiment with
primary tumours we did not challenge the
cured mice with the tumour; thus we
cannot know whether these mice were
specifically immune towards it.
The results reported here show the im-
portance of the use of primary tumours
induced by low doses of carcinogen for
testing tumour immunotherapy systems.
The transplantation of the tumour fre-
quently modifies at least one of the pri-
mary tumour characteristics which is
necessary to BCG action. The tumours
sensitive to BCG, in general, are induced
by a low dose of MCA (0-01 mg); their
characteristics are a slow growth rate and
a tendency towards a low immuno-
genicity, which are both probably related
to a low malignancy, as some of them
regress spontaneously.
Primary tumours induced by low doses
of carcinogen having a low or high rate of
disappearance in the host have to be
studied for their short or long latent
period, their slow or rapid growth rate and
theirlow or high immunogenicity, with the
aim of controlling the immunotherapy
and of achieving a better transfer of
experimental observations to conditions
in humans.
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